Payment overview · 2025
General Payments
$1,779.06
71 reported records · 14 companies
Healthcare provider profile · identity verified
Wilbert Timothy Tsai, MD
Allopathic & Osteopathic Physicians|Family Medicine · POMONA, CA · NPI 1013114420
Verified facts
What the public records show
CMS Open Payments records show Wilbert Timothy Tsai, MD received $1,779.06 in general payments during 2025 across 71 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Linzess, Mounjaro, Ozempic, Trelegy Ellipta, Verquvo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Verquvo by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RELISTOR as an associated drug or biological on 23206 records involving 6246 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Relistor by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $483.59 | 27.2% | 14 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $364.48 | 20.5% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $197.53 | 11.1% | 7 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $182.98 | 10.3% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $114.45 | 6.4% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $101.22 | 5.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $77.49 | 4.4% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $61.07 | 3.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $56.44 | 3.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $42.15 | 2.4% | 2 | 2025 |
| Alvogen Inc | Unresolved — no canonical attribution shown | $36.22 | 2.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.49 | 1.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.47 | 1.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.48 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,779.06 | 71 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $260.59 | 8 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $182.98 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $178.63 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $152.96 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $149.52 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $114.45 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $112.89 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $112.89 | 10 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $102.07 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $89.74 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $62.26 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $62.26 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $62.09 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $61.07 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $56.44 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $53.25 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $38.96 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $38.94 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $36.48 | 2 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Alvogen Inc | $36.22 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $24.71 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.86 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.47 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 116 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 52 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 87 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 122 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 63 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
34 | 25 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
52 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
87 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
122 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
116 | 47 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | RELISTOR open payments reported associated product |
CMS Open Payments — General Payments 23206 supporting records · 6246 recipient NPIs · example record 1231775437 |
Relistor · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 566 | 150 |
| Losartan Potassium | Losartan Potassium | 367 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 306 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 292 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 184 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 180 | 49 |
| Furosemide | Furosemide | 165 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 164 | 45 |
| Gabapentin | Gabapentin | 151 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 39 |
| Ozempic | Semaglutide | 122 | 24 |
| Eliquis | Apixaban | 116 | 47 |
| Omeprazole | Omeprazole | 112 | 32 |
| Lisinopril | Lisinopril | 102 | 23 |
| Carvedilol | Carvedilol | 91 | 31 |
| Mounjaro | Tirzepatide | 87 | 14 |
| Metformin Hcl | Metformin Hcl | 86 | 23 |
| Mirtazapine | Mirtazapine | 83 | 28 |
| Tramadol Hcl | Tramadol Hcl | 83 | 40 |
| Atenolol | Atenolol | 80 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 69 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 19 |
| Simvastatin | Simvastatin | 63 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 15 |
| Alprazolam | Alprazolam | 62 | 14 |
| Potassium Chloride | Potassium Chloride | 58 | 17 |
| Montelukast Sodium | Montelukast Sodium | 55 | 13 |
| Lorazepam | Lorazepam | 54 | 16 |
| Levetiracetam | Levetiracetam | 53 | 11 |
| Spironolactone | Spironolactone | 53 | 14 |
| Farxiga | Dapagliflozin Propanediol | 52 | 20 |
| Donepezil Hcl | Donepezil Hcl | 51 | 16 |
| Famotidine | Famotidine | 51 | 17 |
| Finasteride | Finasteride | 48 | 14 |
| Meloxicam | Meloxicam | 47 | 17 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 44 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 42 | 18 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 42 | 13 |
| Memantine Hcl | Memantine Hcl | 41 | suppressed |
| Azithromycin | Azithromycin | 40 | 33 |
| Entresto | Sacubitril/Valsartan | 40 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 37 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Jardiance | Empagliflozin | 34 | 13 |
| Linzess | Linaclotide | 34 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 34 | 14 |
| Prednisone | Prednisone | 34 | 22 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Prolia | Denosumab | 34 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 32 | 11 |
| Allopurinol | Allopurinol | 31 | suppressed |
| Naproxen | Naproxen | 30 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 17 |
| Xarelto | Rivaroxaban | 29 | 13 |
| Celecoxib | Celecoxib | 28 | 11 |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | 13 |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 22 |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Ezetimibe | Ezetimibe | 24 | 12 |
| Latanoprost | Latanoprost | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | 13 |
| Brilinta | Ticagrelor | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 13 |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 15 | suppressed |
| Repatha Syringe | Evolocumab | 15 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Ampicillin-Sulbactam | Ampicillin Sod/Sulbactam Sod | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Verquvo | Vericiguat | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Relistor | Methylnaltrexone Bromide | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,779.06 · 71 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPVAXIVE, CREON, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, GEMTESA, KISUNLA, KRYSTEXXA, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TERIPARATIDE, TRELEGY ELLIPTA, UBRELVY, VERQUVO, Veozah, XIFAXAN, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error